Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02211508 · ClinicalTrials.gov registry record · NA
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301
A NA study, sponsored by Cerephex Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 236
- Enrollment target
NCT02211508: Clinical Trial NA study, sponsored by Cerephex Corporation.
NCT02211508 is a NA study that was terminated before completion, run by Cerephex Corporation. The registered enrollment target is 236 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02211508, a NA study, was terminated before completion, sponsored by Cerephex Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 236 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of a noninvasive cortical electrostimulation therapy known as "Reduced Impedance Noninvasive Cortical Electrostimulation" (RINCE) in the treatment of pain associated with fibromyalgia. Patients who meet the 2010 American College of Rheumatology criteria for fibromyalgia will receive up to 24 RINCE treatments delivered by a medical device called "NeuroPoint". Approximately 200 fibromyalgia patients will be randomized into one of two study groups. One of these groups will receive sham treatment, meaning they will receive no treatment at all, while the other group will receive active RINCE treatment. The study's primary outcome measure will be the difference between active and sham treatment groups in the mean change from baseline in patients' weekly worst pain scores. The study's hypothesis is that there will be a difference between treatment groups in primary outcome measure.
Primary Outcome
The primary efficacy endpoint will be the contrast at 12 weeks versus Baseline in the (paired) mean weekly change in patients' self-reported daily (24-hour) recall worst pain intensity using an 11-point (0-10) numerical rating scale.
Interventions
- DEVICE RINCE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-02 |
| Phase | NA |
Why NCT02211508 stopped before completion
NCT02211508 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which RINCE is the first listed.
NCT02211508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02211508 about?
NCT02211508 is a clinical study titled "Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301". The purpose of this study is to test the safety and efficacy of a noninvasive cortical electrostimulation therapy known as "Reduced Impedance Noninvasive Cortical Electrostimulation" (RINCE) in the treatment of pain associated with fibromyalgia. Patients who meet the 2010 American College of Rheumat...
What is the current status of trial NCT02211508?
This trial is currently terminated. It is a NA study. The enrollment target is 236 participants. The study started on 2014-07. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02211508?
The interventions under investigation include: RINCE (DEVICE).
Who is sponsoring clinical trial NCT02211508?
This trial is sponsored by Cerephex Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02211508's enrollment target sits among peer trials
236 461st of 2000 higher than 1,540 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia